In a surprising twist of events, indie game Schedule I has found itself at the center of a copyright infringement accusation by Movie Games S.A., the developers behind the popular The Drug Dealer Simulator series. According to a report from the Polish Press Agency dated April 3, Movie Games S.A. alleges that Schedule I may have infringed upon their intellectual property rights, claiming similarities in plot, game mechanics, and user interface. While the legal proceedings are yet to unfold, the gaming community has already taken sides, and it appears that Schedule I has garnered significant support.

In a remarkable show of solidarity, fans have initiated a review bombing campaign against Movie Games S.A.'s titles, The Drug Dealer Simulator and Drug Dealer Simulator 2. As a result, both games are now rated "Overwhelmingly Negative" and "Mostly Negative" on Steam, respectively. The backlash primarily focuses on accusations of Movie Games S.A. bullying the indie developer behind Schedule I and their perceived hypocrisy, especially given that similar games existed before Schedule I without facing legal action. Despite this, The Drug Dealer Simulator series has been widely praised as one of the best criminal management games in the industry.

Schedule I Recent Updates

Schedule I’s Copyright Infringement Accuser Gets Review Bombed on Steam

Schedule I, a new cooperative crime simulation game, allows players to embark on a journey from a small-time dope pusher to a kingpin. Launched into Early Access on PC on March 25, the game has quickly climbed the ranks to become Steam's second top-selling title, surpassing heavyweights like inZOI, Monster Hunter Wilds, and the indie hit R.E.P.O.. With an all-time peak of 459,075 concurrent players, according to SteamDB, Schedule I has received "Overwhelmingly Positive" reviews on Steam, showcasing its popularity and player satisfaction.

Here at Game8, we've found Schedule I to be an unexpectedly addictive and rewarding experience, earning it the nickname of a "Breaking Bad" simulator. For a deeper dive into our impressions on Schedule I's Early Access release, be sure to check out our detailed article below.